nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—OPRM1—nicotine dependence	0.799	1	CbGaD
Ondansetron—Blindness transient—Varenicline—nicotine dependence	0.0147	0.135	CcSEcCtD
Ondansetron—Electrocardiogram ST segment depression—Varenicline—nicotine dependence	0.0119	0.109	CcSEcCtD
Ondansetron—Sleep disturbance—Varenicline—nicotine dependence	0.0048	0.044	CcSEcCtD
Ondansetron—HTR3A—Ligand-gated ion channel transport—GABRA4—nicotine dependence	0.00474	0.0614	CbGpPWpGaD
Ondansetron—Ventricular extrasystoles—Varenicline—nicotine dependence	0.00298	0.0273	CcSEcCtD
Ondansetron—CYP2E1—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00278	0.0359	CbGpPWpGaD
Ondansetron—Musculoskeletal pain—Varenicline—nicotine dependence	0.00273	0.025	CcSEcCtD
Ondansetron—CYP3A7—Xenobiotics—CYP2A7—nicotine dependence	0.00238	0.0308	CbGpPWpGaD
Ondansetron—HTR4—Monoamine GPCRs—DRD2—nicotine dependence	0.00237	0.0307	CbGpPWpGaD
Ondansetron—HTR4—brain—nicotine dependence	0.00231	0.158	CbGeAlD
Ondansetron—Sleep disorder—Varenicline—nicotine dependence	0.00226	0.0207	CcSEcCtD
Ondansetron—Visual disturbance—Varenicline—nicotine dependence	0.00206	0.0189	CcSEcCtD
Ondansetron—Atrial fibrillation—Varenicline—nicotine dependence	0.00206	0.0189	CcSEcCtD
Ondansetron—HTR4—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00199	0.0258	CbGpPWpGaD
Ondansetron—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00197	0.0255	CbGpPWpGaD
Ondansetron—CYP2C9—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00195	0.0253	CbGpPWpGaD
Ondansetron—Urinary retention—Varenicline—nicotine dependence	0.00186	0.017	CcSEcCtD
Ondansetron—Liver function test abnormal—Varenicline—nicotine dependence	0.0018	0.0165	CcSEcCtD
Ondansetron—Hypokalaemia—Varenicline—nicotine dependence	0.00178	0.0163	CcSEcCtD
Ondansetron—SLC47A2—brain—nicotine dependence	0.00175	0.12	CbGeAlD
Ondansetron—CYP2E1—Xenobiotics—CYP2A7—nicotine dependence	0.00172	0.0223	CbGpPWpGaD
Ondansetron—CYP3A5—Xenobiotics—CYP2A7—nicotine dependence	0.00172	0.0222	CbGpPWpGaD
Ondansetron—Asthma—Varenicline—nicotine dependence	0.00169	0.0155	CcSEcCtD
Ondansetron—Angina pectoris—Varenicline—nicotine dependence	0.00165	0.0151	CcSEcCtD
Ondansetron—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.00154	0.0199	CbGpPWpGaD
Ondansetron—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.00149	0.0137	CcSEcCtD
Ondansetron—Acute coronary syndrome—Varenicline—nicotine dependence	0.00148	0.0136	CcSEcCtD
Ondansetron—Myocardial infarction—Varenicline—nicotine dependence	0.00148	0.0135	CcSEcCtD
Ondansetron—Hepatobiliary disease—Varenicline—nicotine dependence	0.00142	0.0131	CcSEcCtD
Ondansetron—Bradycardia—Varenicline—nicotine dependence	0.00138	0.0126	CcSEcCtD
Ondansetron—Visual impairment—Varenicline—nicotine dependence	0.0013	0.0119	CcSEcCtD
Ondansetron—Erythema multiforme—Varenicline—nicotine dependence	0.00128	0.0117	CcSEcCtD
Ondansetron—Eye disorder—Varenicline—nicotine dependence	0.00126	0.0116	CcSEcCtD
Ondansetron—Cardiac disorder—Varenicline—nicotine dependence	0.00125	0.0115	CcSEcCtD
Ondansetron—Angiopathy—Varenicline—nicotine dependence	0.00123	0.0112	CcSEcCtD
Ondansetron—Immune system disorder—Varenicline—nicotine dependence	0.00122	0.0112	CcSEcCtD
Ondansetron—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00122	0.0158	CbGpPWpGaD
Ondansetron—Mediastinal disorder—Varenicline—nicotine dependence	0.00122	0.0112	CcSEcCtD
Ondansetron—Chills—Varenicline—nicotine dependence	0.00121	0.0111	CcSEcCtD
Ondansetron—CYP2C9—Xenobiotics—CYP2A7—nicotine dependence	0.00121	0.0157	CbGpPWpGaD
Ondansetron—Arrhythmia—Varenicline—nicotine dependence	0.00121	0.0111	CcSEcCtD
Ondansetron—Erythema—Varenicline—nicotine dependence	0.00118	0.0108	CcSEcCtD
Ondansetron—Flatulence—Varenicline—nicotine dependence	0.00116	0.0106	CcSEcCtD
Ondansetron—Vision blurred—Varenicline—nicotine dependence	0.00111	0.0102	CcSEcCtD
Ondansetron—Tremor—Varenicline—nicotine dependence	0.0011	0.0101	CcSEcCtD
Ondansetron—Ill-defined disorder—Varenicline—nicotine dependence	0.00109	0.01	CcSEcCtD
Ondansetron—Agitation—Varenicline—nicotine dependence	0.00108	0.00992	CcSEcCtD
Ondansetron—Angioedema—Varenicline—nicotine dependence	0.00108	0.00986	CcSEcCtD
Ondansetron—HTR1B—cardiovascular system—nicotine dependence	0.00106	0.0729	CbGeAlD
Ondansetron—Malaise—Varenicline—nicotine dependence	0.00106	0.00973	CcSEcCtD
Ondansetron—Syncope—Varenicline—nicotine dependence	0.00106	0.00968	CcSEcCtD
Ondansetron—Palpitations—Varenicline—nicotine dependence	0.00104	0.00954	CcSEcCtD
Ondansetron—Loss of consciousness—Varenicline—nicotine dependence	0.00103	0.00948	CcSEcCtD
Ondansetron—CYP1A2—Xenobiotics—CYP2A7—nicotine dependence	0.00103	0.0134	CbGpPWpGaD
Ondansetron—HTR3A—Ion channel transport—GABRA4—nicotine dependence	0.00103	0.0133	CbGpPWpGaD
Ondansetron—Cough—Varenicline—nicotine dependence	0.00103	0.00942	CcSEcCtD
Ondansetron—Convulsion—Varenicline—nicotine dependence	0.00102	0.00935	CcSEcCtD
Ondansetron—HTR3A—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00102	0.0132	CbGpPWpGaD
Ondansetron—Chest pain—Varenicline—nicotine dependence	0.001	0.00919	CcSEcCtD
Ondansetron—Anxiety—Varenicline—nicotine dependence	0.000999	0.00916	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.000995	0.00912	CcSEcCtD
Ondansetron—HTR1B—Monoamine GPCRs—DRD2—nicotine dependence	0.000992	0.0128	CbGpPWpGaD
Ondansetron—Discomfort—Varenicline—nicotine dependence	0.00099	0.00908	CcSEcCtD
Ondansetron—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000986	0.0128	CbGpPWpGaD
Ondansetron—HTR4—GPCR ligand binding—TAS2R16—nicotine dependence	0.00098	0.0127	CbGpPWpGaD
Ondansetron—Dry mouth—Varenicline—nicotine dependence	0.00098	0.00899	CcSEcCtD
Ondansetron—CYP3A7—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000973	0.0126	CbGpPWpGaD
Ondansetron—Shock—Varenicline—nicotine dependence	0.000945	0.00866	CcSEcCtD
Ondansetron—Nervous system disorder—Varenicline—nicotine dependence	0.000942	0.00864	CcSEcCtD
Ondansetron—Tachycardia—Varenicline—nicotine dependence	0.000937	0.0086	CcSEcCtD
Ondansetron—Skin disorder—Varenicline—nicotine dependence	0.000933	0.00855	CcSEcCtD
Ondansetron—OPRM1—midbrain—nicotine dependence	0.000908	0.0622	CbGeAlD
Ondansetron—Hypotension—Varenicline—nicotine dependence	0.000898	0.00823	CcSEcCtD
Ondansetron—HTR1A—cardiovascular system—nicotine dependence	0.000859	0.0588	CbGeAlD
Ondansetron—Dyspnoea—Varenicline—nicotine dependence	0.000856	0.00785	CcSEcCtD
Ondansetron—Somnolence—Varenicline—nicotine dependence	0.000854	0.00783	CcSEcCtD
Ondansetron—HTR1B—Amine ligand-binding receptors—DRD2—nicotine dependence	0.000833	0.0108	CbGpPWpGaD
Ondansetron—HTR1B—midbrain—nicotine dependence	0.000831	0.0569	CbGeAlD
Ondansetron—Gastrointestinal disorder—Varenicline—nicotine dependence	0.000829	0.0076	CcSEcCtD
Ondansetron—Fatigue—Varenicline—nicotine dependence	0.000828	0.00759	CcSEcCtD
Ondansetron—Pain—Varenicline—nicotine dependence	0.000821	0.00753	CcSEcCtD
Ondansetron—Constipation—Varenicline—nicotine dependence	0.000821	0.00753	CcSEcCtD
Ondansetron—CYP3A7—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0008	0.0104	CbGpPWpGaD
Ondansetron—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.000798	0.0103	CbGpPWpGaD
Ondansetron—Feeling abnormal—Varenicline—nicotine dependence	0.000792	0.00726	CcSEcCtD
Ondansetron—Gastrointestinal pain—Varenicline—nicotine dependence	0.000785	0.0072	CcSEcCtD
Ondansetron—KCNH2—cardiovascular system—nicotine dependence	0.000765	0.0524	CbGeAlD
Ondansetron—Urticaria—Varenicline—nicotine dependence	0.000763	0.007	CcSEcCtD
Ondansetron—Body temperature increased—Varenicline—nicotine dependence	0.000759	0.00696	CcSEcCtD
Ondansetron—Abdominal pain—Varenicline—nicotine dependence	0.000759	0.00696	CcSEcCtD
Ondansetron—HTR1A—Monoamine GPCRs—DRD2—nicotine dependence	0.000755	0.00978	CbGpPWpGaD
Ondansetron—SLC47A2—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000733	0.00949	CbGpPWpGaD
Ondansetron—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000714	0.00925	CbGpPWpGaD
Ondansetron—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000713	0.00923	CbGpPWpGaD
Ondansetron—Hypersensitivity—Varenicline—nicotine dependence	0.000708	0.00649	CcSEcCtD
Ondansetron—CYP2E1—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000705	0.00913	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.000704	0.00912	CbGpPWpGaD
Ondansetron—CYP3A5—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000704	0.00911	CbGpPWpGaD
Ondansetron—Asthenia—Varenicline—nicotine dependence	0.000689	0.00632	CcSEcCtD
Ondansetron—Pruritus—Varenicline—nicotine dependence	0.00068	0.00623	CcSEcCtD
Ondansetron—HTR3A—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.000678	0.00878	CbGpPWpGaD
Ondansetron—HTR1B—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.000677	0.00876	CbGpPWpGaD
Ondansetron—KCNH2—Neuronal System—CHRNB3—nicotine dependence	0.000673	0.00872	CbGpPWpGaD
Ondansetron—HTR1A—midbrain—nicotine dependence	0.000671	0.0459	CbGeAlD
Ondansetron—Diarrhoea—Varenicline—nicotine dependence	0.000657	0.00603	CcSEcCtD
Ondansetron—KCNH2—Neuronal System—CHRNA6—nicotine dependence	0.000638	0.00826	CbGpPWpGaD
Ondansetron—Dizziness—Varenicline—nicotine dependence	0.000635	0.00582	CcSEcCtD
Ondansetron—HTR1A—Amine ligand-binding receptors—DRD2—nicotine dependence	0.000635	0.00822	CbGpPWpGaD
Ondansetron—HTR4—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000633	0.0082	CbGpPWpGaD
Ondansetron—HTR3A—brain—nicotine dependence	0.000622	0.0426	CbGeAlD
Ondansetron—CYP2C9—cardiovascular system—nicotine dependence	0.000621	0.0426	CbGeAlD
Ondansetron—HTR3A—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.000616	0.00797	CbGpPWpGaD
Ondansetron—SLC47A1—brain—nicotine dependence	0.000611	0.0419	CbGeAlD
Ondansetron—Vomiting—Varenicline—nicotine dependence	0.000611	0.0056	CcSEcCtD
Ondansetron—Rash—Varenicline—nicotine dependence	0.000606	0.00555	CcSEcCtD
Ondansetron—Dermatitis—Varenicline—nicotine dependence	0.000605	0.00555	CcSEcCtD
Ondansetron—Headache—Varenicline—nicotine dependence	0.000602	0.00552	CcSEcCtD
Ondansetron—KCNH2—midbrain—nicotine dependence	0.000597	0.0409	CbGeAlD
Ondansetron—OPRM1—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.000597	0.00773	CbGpPWpGaD
Ondansetron—CYP2E1—cardiovascular system—nicotine dependence	0.000589	0.0403	CbGeAlD
Ondansetron—CYP2E1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000579	0.0075	CbGpPWpGaD
Ondansetron—CYP3A5—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000578	0.00748	CbGpPWpGaD
Ondansetron—OPRM1—brain—nicotine dependence	0.000571	0.0391	CbGeAlD
Ondansetron—HTR4—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000554	0.00717	CbGpPWpGaD
Ondansetron—HTR4—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000543	0.00703	CbGpPWpGaD
Ondansetron—HTR1B—brain—nicotine dependence	0.000522	0.0358	CbGeAlD
Ondansetron—HTR1A—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.000515	0.00667	CbGpPWpGaD
Ondansetron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000507	0.00656	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—TAS2R16—nicotine dependence	0.000503	0.00651	CbGpPWpGaD
Ondansetron—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000503	0.00651	CbGpPWpGaD
Ondansetron—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.0005	0.00648	CbGpPWpGaD
Ondansetron—CYP2C9—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000496	0.00642	CbGpPWpGaD
Ondansetron—SLC47A1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000472	0.00612	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00047	0.00609	CbGpPWpGaD
Ondansetron—KCNH2—Neuronal System—GABRA4—nicotine dependence	0.000461	0.00598	CbGpPWpGaD
Ondansetron—HTR4—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000458	0.00593	CbGpPWpGaD
Ondansetron—CYP3A7—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000451	0.00583	CbGpPWpGaD
Ondansetron—KCNH2—Neuronal System—CHRNB4—nicotine dependence	0.000442	0.00573	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.000442	0.00572	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—FGD1—nicotine dependence	0.000435	0.00563	CbGpPWpGaD
Ondansetron—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000429	0.00556	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.000427	0.00553	CbGpPWpGaD
Ondansetron—CYP3A7—Biological oxidations—CYP2A7—nicotine dependence	0.000425	0.0055	CbGpPWpGaD
Ondansetron—CYP1A2—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000424	0.00549	CbGpPWpGaD
Ondansetron—HTR1A—brain—nicotine dependence	0.000421	0.0289	CbGeAlD
Ondansetron—CYP3A7—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000419	0.00542	CbGpPWpGaD
Ondansetron—HTR4—GPCR ligand binding—OPRM1—nicotine dependence	0.000413	0.00535	CbGpPWpGaD
Ondansetron—KCNH2—Neuronal System—CHRNA5—nicotine dependence	0.000411	0.00533	CbGpPWpGaD
Ondansetron—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000411	0.00532	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—TAS2R16—nicotine dependence	0.00041	0.0053	CbGpPWpGaD
Ondansetron—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000407	0.00528	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—FGD1—nicotine dependence	0.000395	0.00511	CbGpPWpGaD
Ondansetron—HTR4—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000392	0.00508	CbGpPWpGaD
Ondansetron—KCNH2—brain—nicotine dependence	0.000375	0.0257	CbGeAlD
Ondansetron—OPRM1—GPCR ligand binding—TAS2R16—nicotine dependence	0.000361	0.00468	CbGpPWpGaD
Ondansetron—HTR3A—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000358	0.00463	CbGpPWpGaD
Ondansetron—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000348	0.00451	CbGpPWpGaD
Ondansetron—KCNH2—Neuronal System—CHRNA3—nicotine dependence	0.000335	0.00434	CbGpPWpGaD
Ondansetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000331	0.00429	CbGpPWpGaD
Ondansetron—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000327	0.00424	CbGpPWpGaD
Ondansetron—CYP2E1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000326	0.00423	CbGpPWpGaD
Ondansetron—CYP3A5—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000326	0.00422	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—TAS2R16—nicotine dependence	0.000312	0.00404	CbGpPWpGaD
Ondansetron—CYP2E1—Biological oxidations—CYP2A7—nicotine dependence	0.000308	0.00398	CbGpPWpGaD
Ondansetron—CYP3A5—Biological oxidations—CYP2A7—nicotine dependence	0.000307	0.00398	CbGpPWpGaD
Ondansetron—CYP2E1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000303	0.00393	CbGpPWpGaD
Ondansetron—CYP3A5—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000303	0.00392	CbGpPWpGaD
Ondansetron—HTR4—GPCR ligand binding—DRD2—nicotine dependence	0.000299	0.00387	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—TAS2R16—nicotine dependence	0.000297	0.00385	CbGpPWpGaD
Ondansetron—KCNH2—Neuronal System—CHRNB2—nicotine dependence	0.000295	0.00382	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.000295	0.00382	CbGpPWpGaD
Ondansetron—CYP2E1—brain—nicotine dependence	0.000289	0.0198	CbGeAlD
Ondansetron—HTR1B—G alpha (i) signalling events—OPRM1—nicotine dependence	0.000285	0.00369	CbGpPWpGaD
Ondansetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000269	0.00348	CbGpPWpGaD
Ondansetron—KCNH2—Neuronal System—CHRNA4—nicotine dependence	0.000268	0.00347	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.000268	0.00347	CbGpPWpGaD
Ondansetron—HTR1B—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000265	0.00343	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—OPRM1—nicotine dependence	0.000234	0.00302	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—FGD1—nicotine dependence	0.000233	0.00302	CbGpPWpGaD
Ondansetron—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000232	0.003	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000231	0.003	CbGpPWpGaD
Ondansetron—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00023	0.00297	CbGpPWpGaD
Ondansetron—CYP2D6—brain—nicotine dependence	0.000229	0.0157	CbGeAlD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000227	0.00294	CbGpPWpGaD
Ondansetron—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.000218	0.00283	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—OPRM1—nicotine dependence	0.000217	0.00281	CbGpPWpGaD
Ondansetron—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.000216	0.0028	CbGpPWpGaD
Ondansetron—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000215	0.00279	CbGpPWpGaD
Ondansetron—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000213	0.00276	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—OPRM1—nicotine dependence	0.000212	0.00275	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—TAS2R16—nicotine dependence	0.00021	0.00272	CbGpPWpGaD
Ondansetron—HTR1B—G alpha (i) signalling events—DRD2—nicotine dependence	0.000206	0.00267	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—AKR1B10—nicotine dependence	0.000206	0.00267	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000204	0.00265	CbGpPWpGaD
Ondansetron—HTR1A—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000202	0.00261	CbGpPWpGaD
Ondansetron—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000196	0.00254	CbGpPWpGaD
Ondansetron—HTR1B—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000191	0.00248	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—TAS2R16—nicotine dependence	0.000186	0.0024	CbGpPWpGaD
Ondansetron—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	0.000185	0.00239	CbGpPWpGaD
Ondansetron—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000182	0.00236	CbGpPWpGaD
Ondansetron—OPRM1—G alpha (i) signalling events—DRD2—nicotine dependence	0.000182	0.00236	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—FGD1—nicotine dependence	0.000182	0.00235	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000176	0.00228	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000173	0.00224	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—OPRM1—nicotine dependence	0.000173	0.00224	CbGpPWpGaD
Ondansetron—OPRM1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000169	0.00219	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—DRD2—nicotine dependence	0.000169	0.00219	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—FGD1—nicotine dependence	0.000165	0.00214	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000164	0.00212	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—FGD1—nicotine dependence	0.00016	0.00208	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—TAS2R16—nicotine dependence	0.00016	0.00207	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—DRD2—nicotine dependence	0.000157	0.00203	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—DRD2—nicotine dependence	0.000153	0.00199	CbGpPWpGaD
Ondansetron—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000151	0.00196	CbGpPWpGaD
Ondansetron—HTR1A—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000146	0.00189	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—FGD1—nicotine dependence	0.000146	0.00188	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—WASF2—nicotine dependence	0.000145	0.00188	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000145	0.00187	CbGpPWpGaD
Ondansetron—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000143	0.00185	CbGpPWpGaD
Ondansetron—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000141	0.00182	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—WASF1—nicotine dependence	0.000139	0.0018	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—FGD1—nicotine dependence	0.000138	0.00179	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—OPRM1—nicotine dependence	0.000132	0.0017	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—FGD1—nicotine dependence	0.000126	0.00163	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—OPRM1—nicotine dependence	0.000125	0.00162	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000125	0.00162	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—DRD2—nicotine dependence	0.000125	0.00162	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TAS2R16—nicotine dependence	0.000124	0.00161	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—DRD2—nicotine dependence	0.00011	0.00143	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TAS2R16—nicotine dependence	0.00011	0.00142	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—OPRM1—nicotine dependence	9.76e-05	0.00126	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—FGD1—nicotine dependence	9.74e-05	0.00126	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—DRD2—nicotine dependence	9.51e-05	0.00123	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TAS2R16—nicotine dependence	9.46e-05	0.00122	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—DRD2—nicotine dependence	9.06e-05	0.00117	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—OPRM1—nicotine dependence	8.86e-05	0.00115	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—AKR1B10—nicotine dependence	8.61e-05	0.00111	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—FGD1—nicotine dependence	8.6e-05	0.00111	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—AKR1B10—nicotine dependence	7.6e-05	0.000984	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—OPRM1—nicotine dependence	7.43e-05	0.000963	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—FGD1—nicotine dependence	7.42e-05	0.000961	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—CYP2A7—nicotine dependence	7.26e-05	0.000941	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—DRD2—nicotine dependence	7.05e-05	0.000914	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—OPRM1—nicotine dependence	6.75e-05	0.000874	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—AKR1B10—nicotine dependence	6.56e-05	0.000849	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—DRD2—nicotine dependence	6.41e-05	0.00083	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—DRD2—nicotine dependence	6.23e-05	0.000806	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—WASF2—nicotine dependence	6.06e-05	0.000785	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—WASF1—nicotine dependence	5.81e-05	0.000753	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—DRD2—nicotine dependence	5.65e-05	0.000732	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—DRD2—nicotine dependence	5.37e-05	0.000696	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—WASF2—nicotine dependence	5.35e-05	0.000693	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CYP2A7—nicotine dependence	5.26e-05	0.000681	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CYP2A7—nicotine dependence	5.25e-05	0.00068	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—OPRM1—nicotine dependence	5.23e-05	0.000678	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—WASF1—nicotine dependence	5.13e-05	0.000664	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—DRD2—nicotine dependence	4.88e-05	0.000632	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—WASF2—nicotine dependence	4.62e-05	0.000598	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—WASF1—nicotine dependence	4.43e-05	0.000573	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—OPRM1—nicotine dependence	3.99e-05	0.000516	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—DRD2—nicotine dependence	3.78e-05	0.00049	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CYP2A7—nicotine dependence	3.73e-05	0.000483	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CYP2A7—nicotine dependence	3.7e-05	0.000479	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—DRD2—nicotine dependence	3.34e-05	0.000432	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CYP2A7—nicotine dependence	3.16e-05	0.00041	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—DRD2—nicotine dependence	2.88e-05	0.000373	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP2A7—nicotine dependence	2.44e-05	0.000316	CbGpPWpGaD
